Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies von Costello, Caitlin L., Cohen, Adam D., Patel, Krina K., Ali, Syed S, Berdeja, Jesus G., Shah, Nina, Ganguly, Siddhartha, Kocoglu, Mehmet Hakan, Abedi, Mehrdad, Ostertag, Eric M., Martin, Chris E, Ghoddussi, Majid, Shedlock, Devon J, McCaigue, Joanne, Namini, Hamid, Yalamanchili, Sreeni, Spear, Matthew A., Gregory, Tara K.

Volltext